Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

University of British Columbia

$17,500.00

The role of innate-adaptive and T-B cell interactions in the infant immune response to vaccination.

FY 2010-11

Summary
During the early stages of life, newborns and infants exhibit an increased risk for infection; approximately 2.5 million children die every year from vaccine-preventable diseases. This is largely due to the fact that infants are not vaccinated early enough. This reticence to vaccinate earlier is due to the belief that newborns and young infants do not respond as well as older children to vaccination. It follows logically that improving existing vaccines, or producing new ones that can be given earlier (possibly as early as birth), could potentially save the lives of millions of infants every year. To achieve this, we need to study the body's response to vaccines administered early in life, in order to determine how this can be improved. Determining why some infants respond differently to vaccines will enable the identification of the particular factors that make vaccines given early in life effective. To accomplish this, we are going to do study the infant's response to the Hepatitis B vaccine (HBV). HBV is an ideal model for several reasons. First, Hepatitis B is a serious and constant global health threat. Secondly, there exists a large and consistent percentage (5-10%) of vaccinated infants who do not produce the desired protective immune response; this sample is necessary for any examination. Using cell samples collected from newborns and infants, we will systematically investigate how each infant responded to HBV vaccination, and then determine the causes of the differences in reaction between those who respond well, and those who do not. Once these causes are understood, it will be possible to identify the key components of the infant's immune system, which determine whether vaccine response will be protective or not. The final goal will be to develop vaccines that can be administered effectively at birth, thereby ensuring that infants are immunized immediately, dramatically reducing the number of babies that die every year from vaccine-preventable infections.
Program
Master's Award: Canada Graduate Scholarships
Location
British Columbia, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
226949
Name
Gelinas Laura
Region
British Columbia
Country
Canada
Orgtype
Research Institution; Institution Paid
Instname2
Infection and Immunity
Theme2
Biomedical
Prcname2
Canada Graduate Scholarships Master's Awards A
Projecttitle
The role of innate-adaptive and T-B cell interactions in the infant immune response to vaccination.
Programtype2
Studentship Programs
Orgnameinp2
University of British Columbia
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Adaptive Immunity; Elisa; Elispot; Flow Cytometry; Hepatitis B Vaccine; Immunological Memory; Infectious Disease; Innate Immunity; Neonatal Immunology; Vaccine Development
Abstract
During the early stages of life, newborns and infants exhibit an increased risk for infection; approximately 2.5 million children die every year from vaccine-preventable diseases. This is largely due to the fact that infants are not vaccinated early enough. This reticence to vaccinate earlier is due to the belief that newborns and young infants do not respond as well as older children to vaccination. It follows logically that improving existing vaccines, or producing new ones that can be given earlier (possibly as early as birth), could potentially save the lives of millions of infants every year. To achieve this, we need to study the body's response to vaccines administered early in life, in order to determine how this can be improved. Determining why some infants respond differently to vaccines will enable the identification of the particular factors that make vaccines given early in life effective. To accomplish this, we are going to do study the infant's response to the Hepatitis B vaccine (HBV). HBV is an ideal model for several reasons. First, Hepatitis B is a serious and constant global health threat. Secondly, there exists a large and consistent percentage (5-10%) of vaccinated infants who do not produce the desired protective immune response; this sample is necessary for any examination. Using cell samples collected from newborns and infants, we will systematically investigate how each infant responded to HBV vaccination, and then determine the causes of the differences in reaction between those who respond well, and those who do not. Once these causes are understood, it will be possible to identify the key components of the infant's immune system, which determine whether vaccine response will be protective or not. The final goal will be to develop vaccines that can be administered effectively at birth, thereby ensuring that infants are immunized immediately, dramatically reducing the number of babies that die every year from vaccine-preventable infections.
Competitiondate
201102
Approvedterm2
1 yr 0 mth
Pinamesdelim
Gelinas, Laura
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~